Anders Kjellberg

Dr. Anders Kjellberg

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
NONicklas Oscarsson
Nicklas Oscarsson
BMBernd Müller
Bernd Müller
ARAnders Rosén
Anders Rosén
PLPär Lodding
Pär Lodding
JMJohan Mölne
Johan Mölne
HSHelén Seeman-Lodding
Helén Seeman-Lodding

1 August 2002 in Journal of Molecular Biology
Verified
Journal Article
Closed access
CSCecilia Svensson
Cecilia Svensson
STSusann Teneberg
Susann Teneberg
CNCarol L. Nilsson
Carol L. Nilsson
Anders KjellbergAnders Kjellberg
Anders Kjellberg
FSFrederick P. Schwarz
Frederick P. Schwarz
UKUte Krengel
Ute Krengel

9 January 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
HBHelena Bergsten
Helena Bergsten
MMMartin Bruun Madsen
Martin Bruun Madsen
FBFrancois Bergey
Francois Bergey
OHOle Hyldegaard
Ole Hyldegaard
SSSteinar Skrede
Steinar Skrede
VSVítor Martins Dos Santos
Vítor Martins Dos Santos
Analyses of plasma collected pre- and postadministration of intravenous immunoglobulin (IVIG) from patients with group A Streptococcus necrotizing soft tissue infections demonstrated a negative correlation between IVIG dose and toxin-triggered T-cell proliferation (r = −.67, P < .0001). One 25-g IVIG dose was sufficient to yield plasma-neutralizing activity against streptococcal superantigens.Clinical Trials Registration. NCT 01790698 and NCT02111161.

20 January 2023 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Anders KjellbergAnders Kjellberg
Anders Kjellberg
AHAdrian Hassler
Adrian Hassler
EBEmil Boström
Emil Boström
SGSara El Gharbi
Sara El Gharbi
SASarah Al-Ezerjawi
Sarah Al-Ezerjawi
PLPeter Lindholm
Peter Lindholm
Background: With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO2) is a candidate drug. Methods: The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO2 for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO2 or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test. Results: Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60–40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358–525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort. Conclusions: An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO2 to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448 . EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE

1 May 1997 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
MBMalin Bäckström
Malin Bäckström
VSVafa Shahabi
Vafa Shahabi
SJSusanne Johansson
Susanne Johansson
STSusann Teneberg
Susann Teneberg
Anders KjellbergAnders Kjellberg
Anders Kjellberg
MLMichael Richard Lebens
Michael Richard Lebens
The closely related B-subunits of cholera toxin (CTB) and Escherichia coli heat-labile enterotoxin (LTB) both bind strongly to GM1 ganglioside receptors but LTB can also bind to additional glycolipid...

1 November 2020 in Medical Hypotheses
Verified
Journal Article
Open access
Anders KjellbergAnders Kjellberg
Anders Kjellberg
AMAntonio De Maio
Antonio De Maio
PLPeter Lindholm
Peter Lindholm
SARS-CoV-2 affects part of the innate immune response and activates an inflammatory cascade stimulating the release of cytokines and chemokines, particularly within the lung. Indeed, the inflammatory response during COVID-19 is likely the cause for the development of acute respiratory distress syndrome (ARDS). Patients with mild symptoms also show significant changes on pulmonary CT-scan suggestive of severe inflammatory involvement. The overall hypothesis is that HBO2 is safe and reduces the inflammatory response in COVID-19 pneumonitis by attenuation of the innate immune system, increase hypoxia tolerance and thereby prevent organ failure and reduce mortality. HBO2 is used in clinical practice to treat inflammatory conditions but has not been scientifically evaluated for COVID-19. Experimental and empirical data suggests that HBO2 may reduce inflammatory response in COVID-19. However, there are concerns regarding pulmonary safety in patients with pre-existing viral pneumonitis. Anecdotes from “compassionate use” and two published case reports show promising results. Small prospective clinical trials are on the way and we are conducting a randomized clinical trial.